

General information about company

Scrip code*	543916	
NSE Symbol*	NOTLISTED	
MSEI Symbol*	NOTLISTED	
ISIN*	INE0GYI01028	
Name of company	Hemant Surgical Industries Limited	
Type of company	SME	
Class of security	Equity	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Date of board meeting when results were approved	28-05-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	16-05-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Half Yearly	
Reporting Quarter	Yearly	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Single segment	
Description of single segment	Medical Equipment & Supplies	
Start date and time of board meeting	28-05-2025 16:00	
End date and time of board meeting	28-05-2025 19:00	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	No	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	No	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	04-01-2023	
Indicate Company website link for updated RPT policy of the Company	https://hemantsurgical.com/investor-relations/codes-policies	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes	
No. of times funds raised during the quarter	1	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Not Applicable

Financial Results – Other than Bank

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2024	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	5765.6	10652.66
	Other income	270.41	511.24
	Total Income	6036.01	11163.9
2	Expenses		
(a)	Cost of materials consumed	5236.36	9405.56
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1123.98	-1853.83
(d)	Employee benefit expense	506.63	932.62
(e)	Finance costs	143.41	220.43
(f)	Depreciation and amortisation expense	73.9	142.49
(g)	Other Expenses		
1	Others	591.96	1261.09
	Total other expenses	591.96	1261.09
	Total expenses	5428.28	10108.36
3	Profit before exceptional and extraordinary items and tax	607.73	1055.54
4	Exceptional items	0	0
5	Profit before extraordinary items and tax	607.73	1055.54
6	Extraordinary items	0	0
7	Profit before tax	607.73	1055.54
8	Tax Expense		
	Current tax	152.25	264.96
	Deferred tax	-39.5	-22.63
	Total tax expenses	112.75	242.33
9	Net Profit Loss for the period from continuing operations	494.98	813.21
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax	0	0
13	Profit (loss) for period before minority interest	494.98	813.21
14	Share of profit (loss) of associates		
15	Profit (loss) of minority interest		
16	Net profit (Loss) for the period	494.98	813.21
17	Details of equity share capital		
	Paid-up equity share capital	1044	1044
	Face value of equity share capital	10	10
	Details of debt securities		
18	Reserves excluding revaluation reserve		0.00
19	Earnings per equity share (for continuing and discontinued operations)		

	Basic earnings (loss) per share from continuing and discontinued operations		4.74	7.79
	Diluted earnings (loss) per share from continuing and discontinued operations		4.74	7.79
20	Debt equity ratio	0		0 Textual Information(1)
21	Debt service coverage ratio	0		0 Textual Information(2)
22	Interest service coverage ratio	0		0 Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities

	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1044
	Reserves and surplus	5255.03
	Money received against share warrants	0
	Total shareholders' funds	6299.03
2	Share application money pending allotment	0
3	Deferred government grants	0
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	2333.22
	Deferred tax liabilities (net)	0
	Foreign currency monetary item translation difference liability account	0
	Other long-term liabilities	0
	Long-term provisions	54.79
	Total non-current liabilities	2388.01
6	Current liabilities	
	Short-term borrowings	751.11
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	264.87
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	3615.88
	Total Trade payable	3880.75
	Other current liabilities	1060.89
	Short-term provisions	384.55
	Total current liabilities	6077.3
	Total equity and liabilities	14764.34
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	3986.62
	Producing properties	0
	Intangible assets	0
	Preproducing properties	0
	Property, Plant and Equipment capital work-in-progress	1188.15
	Intangible assets under development or work-in-progress	0
	Total Property, Plant and Equipment and Intangible assets	5174.77
(ii)	Non-current investments	145.46
(v)	Deferred tax assets (net)	16.34
(vi)	Foreign currency monetary item translation difference asset account	0
(vii)	Long-term loans and advances	502.62
(viii)	Other non-current assets	124.66
	Total non-current assets	5963.85
2	Current assets	
	Current investments	0

	Inventories	4247.51
	Trade receivables	2031.15
	Cash and cash equivalents	945.69
	Bank balance other than cash and cash equivalents	0
	Short-term loans and advances	767.38
	Other current assets	808.76
	Total current assets	8800.49
	Total assets	14764.34

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2024	01-04-2024
Date of end of reporting period	31-03-2025	31-03-2025
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		

Cash flow statement - indirect

	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before extraordinary items and tax	1055.54
2	Adjustments for reconcile profit (loss)	
	Adjustments to profit (loss)	
	Adjustments for finance costs	214.89
	Adjustments for depreciation and amortisation expense	142.49
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for share-based payments	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	116.53
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments to profit (loss)	473.91
3	Adjustments for working capital	
	Adjustments for decrease (increase) in inventories	-2142.47
	Adjustments for decrease (increase) in trade receivables	142.51
	Adjustments for decrease (increase) in other current assets	-269.81
	Adjustments for increase (decrease) in trade payables	1420.11
	Adjustments for increase (decrease) in other current liabilities	443.68
	Adjustments for provisions	38.33
	Total adjustments for working capital	-367.65
	Total adjustments for reconcile profit (loss)	106.26
	Net cash flows from (used in) operations	1161.8
	Dividends received	0
	Interest paid	0
	Interest received	-59.23
	Income taxes paid (refund)	192.71
	Other inflows (outflows) of cash	-17.8
	Net cash flows from (used in) operating activities before extraordinary items	892.06
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) operating activities	892.06
4	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0

	Proceeds from sales of property plant and equipment	235.11
	Purchase of property plant and equipment	3768.37
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	59.23
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	446.48
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	-3027.55
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	-3027.55
5	Cash flows from used in financing activities	
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	1979.01
	Repayments of borrowings	0
	Dividends paid	0
	Interest paid	214.89
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities before extraordinary items	1764.12
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	1764.12
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-371.37
6	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	-371.37
	Cash and cash equivalents cash flow statement at beginning of period	1317.06
	Cash and cash equivalents cash flow statement at end of period	945.69

Details of Impact of Audit Qualification

Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	ADV and Associates	Yes	29-02-2028

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	31-05-2023
Amount Raised	2484
Report filed for Quarter ended	31-03-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Public Issue Expenses	NIL	313.88	0	313.88	0	
2	To meet Working Capital Requirement	NIL	1000	0	1000	0	
3	Funding Capital Expenditure towards installation	NIL	751.26	0	688.42	0	
4	General Corporate Purpose	NIL	418.86	0	418.86	0	

Signatory Details

Name of signatory	Hanskumar Shamji Shah
Designation of person	Managing Director
Place	Mumbai
Date	28-05-2025

